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ABSTRACT 
Objectives: The study aimed to investigate the gastroprotective effects of a flavonoid rich fraction (FRF) obtained from Achyrocline satureoides. 
Methods: The following protocols were employed: ethanol and NSAID-induced ulcer, ligature pylorus model, and free mucus quantification. Nitric 
oxide (NO) and sulfhydryl group participation were observed by pretreatment with L-NAME or NEM. Besides, it was assayed the acetic acid-induced 
chronic ulcer andthe anti-Helicobacter pyloriactivity in vitro. 
Results: The phytochemical profile of FRF showed three main flavonoids, luteolin, quercetin and 3-O-methyl-quercetin. The administration of FRF 
was able to prevent the damage evoked by ethanol and NSAID-induced ulcer models. The pH and concentration of H+
Conclusions: The results show that FRF provided a significant gastroprotective and ulcer healing activity, mainly due to their capacity to enhance 
mucus secretion.  
 in the stomach were not 
modified by FRF treatment. However, the FRF treatment induces mucus secretion. The effect presented by FRF was mediated by nitric oxide (NO). 
In chronic ulcer model FRF reduced significantly the lesion area, promoting a cure ratio of 65.42±13.00, a similar data presented by cimetidine 
treated animals (61.35±11.88). Using an in vitro assay was observed that FRF at 500 µg/mL was able to inhibit bacterial growth.  
Keywords: Achyrocline satureoides, Gastroprotective, Helicobacter pylori, Flavonoids. 
 
INTRODUCTION 
Gastric ulcer is the most prevalent gastrointestinal tract disease, 
being chronic and often recurring[1,2].Although the etiology of 
gastric ulcer is not completely understood, it is know that 
pathogenesis of gastric ulcers is influenced by several factors as, 
genetic predisposition, altered acid secretion, aged, rapid gastric 
emptying, defective mucosal defense mechanisms, psychological or 
physical stress conditions, inadequate diet, excessive consumption 
of alcohol and non-steroidal anti-inflammatory drugs[3,4].Other 
important aspect of ulcer pathogenesis is the infection with 
Helicobacter pylori, a spiral-shaped flagellated bacterium that live in 
the duodenum and stomach, where promote the generation of 
reactive oxygen species leading a highly inflammatory response[5]. 
The main currently gastric ulcer treatment involves oral 
administration of synthetic histamine receptor antagonists, proton 
pump inhibitors or anticholinergic drugs,and in case of H. pylori 
infection is necessary use of antibiotics[6,3].However, these 
treatments presents high cost and cause many adverse effects. 
Therefore, this search for new therapies is now important and 
natural products are ideal by presenting better protection, low cost 
and lower toxicity [7,8]. 
Achyrocline satureoides(Lam.) DC. (Asteraceae) isa medicinal plant 
popularly known as “marcela”. The infusion obtained from 
inflorescences is widely used to treat stomach disorders such as 
gastric ulcers, as well as to reduce pain and inflammation 
[9,10,11,12,13].In previous studies, our group described thatin vivo 
treatment withA. satureoides hydroalcoholic extract promote 
gastroprotective and anti-inflammatory effects [14,15],without 
presentedacute toxic effects[15].Additionally, the phytochemical 
profile showed that of A. satureoides extract presents steroids, fatty 
acids and mainly flavonoids, as quercetin and luteolin, which are the 
major components of the hydroalcoholic extract. Based on this, we 
show here in the present the gastroprotective and anti-Helicobacter 
pylori activity evoked by a flavonoid rich fraction (FRF) in different 
models of gastric ulcer in animals.  
MATERIAL AND METHODS 
Drugs, reagents and solvents 
Indomethacin, cimetidine, omeprazole, carbenoxolone, NG
Plant material 
-nitro-L-
Arginine methyl-ester (L-NAME) and N-ethyl-maleimide (NEN) were 
purchased from Sigma Aldrich (St. Louis, MD, USA). All the other 
reagents and solvents used were of analytical grade. 
The inflorescences of A. satureoides were collected in Fraiburgo, in 
the state of Santa Catarina, Brazil (Latitude 27°01’34”S, longitude 
50°55’17”W). The material was identified and a voucher specimen 
was deposited at the herbarium of the State University of 
Maringá(UEM) with the code HUEM-23568. 
Preparation of the hydroalcoholic extract and flavonoid rich 
fraction 
Air-dried plant material was cute into small pieces and macerated 
with 70% (v/v) aqueous ethanol at room temperature for 7 days. 
The macerate was filtered and the solvent removed by rotatory 
evaporator under reduced pressure. The FRF was obtained by 
liquid-liquid partition of extract, as follow: extract (20 g) was 
dissolved in methanol:water proportion (9:1), and the liquid-liquid 
extraction process was carried out using hexane (5x300 mL) as 
solvent extractor. After, to obtain the FRF the aqueous residue was 
portioned by liquid-liquid extraction process with ethyl-acetate 
which after drying, resulted in a yield 8.83 g of FRF. 
Apparatus and chromatographic conditions 
A Shimadzu LC-20AT LC system (Shimadzu, Tokyo, Japan), 
consisting of a SPD-M20A photo diode array detector, SIL-20AHT 
International Journal of Pharmacy and Pharmaceutical Sciences 
ISSN- 0975-1491               Vol 6, Issue 7, 2014 
Innovare  
Academic Sciences 
Santin et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 7, 417-422 
418 
autosampler and software LC-Solution (Shimadzu, Tokyo, Japan) 
was used. The sample and standard were diluted in methanol at 1 
mg/mL and filtered through a 0.45-mm PTFE membrane filter. The 
injections of sample and standard (20 L) were carried out on a C18 
column (Luna Phenomenex, 250 x 4,5mm; 0.5μm film thickness and 
100 A) conditioned at 35°C. The mobile phase consisted of 
acetonitrile (A) and water (pH 2.5, phosphoric acid) (B) eluded in a 
gradient system, starting with 10% A (0–4 min), 10–30% A (4–15 
min), 30% A (15–25 min) and 30–10% A (25–30 min). This was 
followed by a 10 min equilibrium period prior to the injection of 
next sample. The analyses were monitored at 350 nm. All solvents 
used were HPLC grade and were degassed in an ultrasonic bath. 
Animals 
Wistar rats male (250-350 g) or Swiss mice male (25-35 g) were 
provided by the Central Animal House of the Universidadeof Vale do 
Itajaí (UNIVALI), Itajaí – SC. The animals were housed in standard 
cages, at room temperature (25±3°C), with 12 h dark/12 h light 
cycles, and supplemented with food and water ad libitum. They were 
transferred to the laboratory 12 hours prior to the experiments and 
were given water ad libitum. In all experiments, the animals were 
kept in cages with raised floors constructed from wide mesh, to 
prevent coprophagy. The experiments were authorized by the 
Ethical Committee for Animal Care (301/09a) of the Universidade of 
Vale do Itajaí, Itajaí, Santa Catarina, Brazil. 
Doses  
The dose used in this study was based in a previous study published 
by our group [14], which demonstrated that 500 mg/kg presents 
significant gastroprotector effect. Besides, this data allows reduction 
in the number of animals used. Thus following the 3Rs program to 1) 
reduction; 2) refinement; 3) replacement, which aims to use fewer 
animals in experiments. 
Gastroprotective activity 
Several methods to evaluate the gastroprotective activity of the FRF 
obtained from A. satureoides were employed. An appropriate 
positive control (omeprazole, a proton pump inhibitor, cimetidine, a 
histamine receptor antagonist or carbenoxolone, an antioxidant) 
was included in every assay. 
Ethanol-induced ulcer gastric 
The experiment was carried out according to the method of 
Morimoto et al.[16]
Non-steroidal anti-inflammatory drugs-induced gastric ulcer 
 After 12 h of fasting, the animals were orally 
treated with vehicle (1% Tween-80 aqueous solution), omeprazole 
(30 mg/kg) or FRF (500 mg/kg). One hour after treatment was 
administered 1 mL of ethanol 99.5% to induce the lesion in the 
gastric tissue. One hour later, the animals were sacrificed, and the 
stomachs were removed and opened along the greater curvature. 
The stomachs were gently rinsed with water to remove the gastric 
contents and blood clots, for subsequent scanning. The images 
obtained were analyzed using specific “EARP” software measure 
each lesion point. 
The experiment was carried out according to the method of 
Nwaforet al.[17] with a few modifications. After 12 h of fasting, the 
animals were orally treated with vehicle (1% Tween-80 aqueous 
solution), cimetidine (100 mg/kg) or FRF (500 mg/kg). One hour 
after treatment was administered indomethacin (100 mg/kg) to 
induce the lesion in the gastric tissue. Four hours after the animals 
were sacrificed and the stomachs were removed, and opened along 
the greater curvature. The stomachs were gently rinsed with water 
to remove the gastric contents and blood clots, for subsequent 
scanning. Was performed determination the total lesion area and 
percentage of injured. 
Acetic acid-induced chronic ulcer 
The methodology described by Takagi et al.[18] was used, with some 
modifications. The mice were anesthetized and subjected to a 
longitudinal incision below the xiphoid process aphophysis. After 
exposure of the stomach, 50µL of 20% acetic acid solution was 
injected into the sub-serosal layer, the site was held down for 30 
seconds to prevent leakage of the injected fluid. The stomach was 
carefully washed with saline 0,9 %and the abdominal wall was 
sutured. Two days after surgery, when the animals had recovered, 
treatment was carried out which lasted seven days. The animals 
were orally treated once a day with vehicle (1% Tween-80 aqueous 
solution), omeprazole (30 mg/kg) or FRF (500 mg/kg). After seven 
days, the animals were sacrificed and the stomachs removed and 
opened along the greater curvature. They were then stretched and 
scanned, to capture images, which were analyzed by image analysis 
software to determine whether regression of the lesion had 
occurred in the treatments, compared with the positive and negative 
controls. Was performed the total lesion area and percentage of 
injured. 
Pyloric ligation-induced gastric ulcer 
The assay was performed using the method of Shay et al.[19], with a 
few modifications. After 24 h of fasting, the animals were 
anesthetized with a mixture of xylazine and ketamine (7.6 mg/kg 
and 77.3 mg/kg, intraperitoneally), the abdomen was incised and 
the pylorus ligated. Immediately after pylorus ligature, the 
treatments were intraduodenally administered vehicle (1% Tween-
80 aqueous solution), omeprazole (30 mg/kg) or FRF (500 mg/kg). 
Four hours later, the animals were sacrificed and the abdomen was 
opened, and another ligature placed at the esophageal end. The 
stomachs were removed and the gastric contents collected and 
centrifuged at 3000 rpm (8000×g, 25◦C, 10 min). The amount of 
gastric-juice acid (mL) and the pH values were determined. Total 
acid secretion in the gastric lesion was determined in the 
supernatant volume by titration to pH 7.0, using a 0.01mol−1
Determination of mucus in gastric content 
NaOH 
solution, and phenolphthalein as indicator. 
This assay was performed according to the methodology described 
previously by Sun et al.[20] with few modifications. After 24 h of 
fasting, under anesthesia, the abdomen was incised and the pylorus 
ligated. Immediately after pylorus ligature, the treatments vehicle, 
carbenoxolone (250 mg/kg) or FRF were intraduodenally 
administered, and the animals were sacrificed 4 h after the drug 
treatments. The stomach content was immersed in 10 mL of 0.02% 
Alcian blue 0.16 M sucrose/0.05 M sodium acetate solution, pH 5.8, 
and incubated for 24 h at 20 ºC. Alcian blue binding extract was 
centrifuged at 3000×g for 10 min. The absorbency of the 
supernatant was measured by spectrophotometry at 615 nm. The 
free mucus in the gastric content was calculated from the amount of 
Alcian blue binding (mg/wt tissue (g)). 
Ethanol-induced gastric mucosal lesion in L-NAME or NEM pre-
treated rats 
These experiments were based on the method of Matsuda et al.[21] 
with some modifications. Male Wistar rats, after fasting for 24 h, 
were treated or not with 70 mg/kg of NO synthase inhibitor (L-
NAME) or 10 mg/kg of sulfhydryl depleter (NEM). Thirty min after 
the pretreatment, the animals were orally treated with vehicle (1% 
Tween-80 aqueous solution) or FRF (500 mg/kg). One hour later1 
mL ethanol99.5% was given to each rodent, and the animals were 
sacrificed after 1 h. The stomachs were removed to determine the 
gastric lesion. 
Anti-Helicobacter pylori activity 
Test materials 
The FRFwas tested to detect the anti-H. pylori activity. The strain of 
H. pylori ATCC 43504 was given by the microorganism reference 
laboratory of Fiocruz-RJ. It was kept frozen at 70⁰C in the 
immunology laboratory at FURB. For activation, it was grown in 
Brucellabroth and incubated at 35⁰C for 24-48 hours. After this 
period, it was inoculated on Brucellaagar supplemented with 10% 
sheep blood and incubated 48-72 hours at 35 ⁰C in microaerophilic 
conditions (85% N2, 10% CO2 and 5% O2) and high humidity. The 
bacterial identification was performed by characteristic morphology 
in Gram staining and biochemical tests of positive catalase, oxidase 
and urease[22]. 
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Determining the Minimum Inhibitory Concentration (MIC) 
The Minimum Inhibitory Concentration (MIC) was determined by 
the agar dilution solid method, according to the recommendations of 
the Clinical Laboratory Standards Institute (CLSI)[23].From stock 
FRF solution of 40 mg/mL, were serially diluted. In individual 
glasses, 50 μL of each dilution was added to 950 μL of Brucella agar 
supplemented with 10% sheeps’ blood, the 45-50⁰C of fluid, 
reaching concentrations of 2000; 1000; 500; 250; 125; 62,5; 31, 25 and 
15,625 μg/mL. The bacterial inoculums were prepared based on a scale 
of 0.5 MacFarland turbidity. After the medium solidification, 1 µL of 
bacterial suspension was seeded in each glass with the diluted extract 
agar. It was incubated in humidity and microaerophilic optimal 
conditions, 35⁰C for 48-72 hours. The MIC was defined as the lowest the 
concentration of fractions capable of completely inhibiting bacterial 
growth. All the experiments were performed in triplicate. 
Statistical analysis 
Results were expressed as mean ± SEM. Statistical significance 
between groups was determined by one-way analysis variance 
(ANOVA) followed by Dunnett’s tests, with p<0.05 considered 
significant. The statistical software program utilized was Graph Pad 
Prism version 6. 
RESULTS  
Chemical profile of FRF 
In the chemical profile of FRF in the Figure 1,threemajor peaks can 
be observed. By co-injection and UV spectra comparison, it was 
possible to suggest the structure of three of these peaks as luteolin, 
quercetin and 3-O-methyl-quercetin. This chemical profile is in 
agreement to what is described in the literature[24]. 
 
 
Fig. 1: HPLC overlap chromatogram profile of FRF. 
 
In vivo FRF treatment protects Ethanol-induced gastric tissue 
damage 
Oral administration of ethanol solution caused lesions in the gastric 
tissue, which were prevented by FRF (500 mg/kg, p.o.) pre-
treatment. It is noteworthy that tissue protection seen with 500 
mg/kg of FRF was better that observed with 30 mg/kg of 
omeprazole (Table 1). 
In vivo FRF treatment protects NSAIDs-induced gastric tissue 
damage 
The data obtained in this model, we observed that the FRF (500 
mg/kg, p.o.) and cimetidine (100 mg/kg, p.o.) significantly reduced 
the percentage of lesion area to 0.70 and 0.33 when compared to 
vehicle group (Table 1), suggesting a gastroprotective effect against 
NSAIDs-induced gastric ulcer.  
 
Table 1:  Effects of FRF, cimetine and omeprazole on the ulcer model induced by ethanol and indomethacin, and chronic ulcer induced by 
acetic acid 






















































Results as mean ± SEM for six rats or mice. Statistical comparison was performed using ANOVA followed by Dunnett´spost test. **
 
p< 0.01 compared 
with the control group 
FRF does not impair acid gastric secretion but induce mucus 
secretion 
The results obtained in this model showed that the FRF (500 mg/kg) 
administered intraduodenally did not promote changes in the 
biochemical parameters of the stomach content, such as pH, 
concentration of H+
This date suggest that the gastroprotective effect exerted is not 
related to reduction of gastric secretion. On the other hand, in the 
mucus determination model, the FRF (500 mg/kg) administered 
 ions and the volume of gastric juice after 
administration (Table 2).  
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intraduodenally promote anincrease in mucus production when 
compared to vehicle and cimetidine treated animals (Table 3). This 
date suggest that the gastroprotective effect could be mediated by an 
increase in mucus production in the stomach. 
 
Table 2: Effects of FRF and cimetidine, administered intraduodenally, on the biochemical parameters of gastric juice obtained from 
pylorus-ligature in rats. 
Treatment (p.o.) Dose (mg/kg) Volume (mL) pH [H+] mEq/I/4h 
Control - 0.77 ± 0.15 2.76 ± 0.13 65.87 ± 2.23 
Cimetidine 100 0.70 ± 0.12 3.92 ± 0.20 46.91 ± 4.38 * 
FRF 500 0.86 ± 0.04 3.03 ± 0.11 76.51 ± 3.55 
Results as mean ± SEM for six rats. Statistical comparison was performed using ANOVA followed by the Dunnett’spost test. *
 
p<0.05 compared with 
the control group 
Table 3:  Effects of FRF and carbenoxolone on Alcian blue 
binding to free gastric mucus from pylorus ligature in rats 
Treatment (v.o) Dose (mg/kg) Alcian blue bound 
(mg/wt tissue (g)) 
Control - 1,41 ± 0,04 
Carbenoxolone 250 1,73 ± 0,02
FRF 
** 
500 1,69 ± 0.04** 
Results as mean ± SEM for six rats. Statistical comparison was 
performed using ANOVA followed by the Dunnett’spos-test.**
 
p<0.01 
compared with the control group. 
FRF gastroprotective effect is mediated by NO 
We observed that the animals pretreated with L-NAME and 
subsequently treated with FRF display exacerbation on lesion area 
when compared to the vehicle group (Figure 2). This data suggest 
that NO is related to the gastroprotective activity promoted by FRF. 
However, we observed that when the animals were pretreated with 
NEM (blocker of sulfhydryl groups) and after treated with FRF did 
not display exacerbation of lesion area, suggesting that the 
sulfhydryl compounds pathway is not involved in the 
gastroprotective effect promoted by FRF. 
FRF treatment promotes healing of chronic ulcer in vivo and 
presents anti-Helicobacter pylori activityin vitro 
Oral administration of FRF (500 mg/kg, p.o.) once a day during 
seven days reduced the chronic gastric ulceration induced by acetic 
acid when compared to vehicle treated animals. The FRF treatment 
promotes a cure rate of 65.42±13.00, a similar data presented by 
cimetidine treated animals (61.35±11.88) (Table 1). Regarding the 
anti-H.pyloripotential of FRF was estimated using the in vitro method 
of solid agar dilution. It was observed that the FRF at 500 µg/mL 
was able to inhibit bacterial growth.  
 
Fig. 2: Effects of FRF on ethanol-induced gastric lesions in rats 
pre-treated with L-NAME or NEM. Results are mean ± SEM for 
six rats.  
Statistical comparison was performed using ANOVA followed by 
Dunnett’s test. ***p<0.01 vs vehicle; ## p<vs L-NAME; &&
DISCUSSION 
p< NEM 
The literature has reported that medicinal plants have a broad 
spectrum of biological activities. Previous studies published by our 
research group showed that A. satureoides hidroalcoholic extract 
obtained from inflorescences present anti-inflammatory and 
gastroprotective activity[14,15]. The A. satureoides hydroalcoholic 
extract presents in its composition flavonoids (luteolin, 3-O-methyl-
quercetin and quercetin), fatty acids (oleic, palmitic and stearic 
acids) and steroids (stigmasterol, gamma-sitosterol, and 
sitosterone)[15]. The literature reports that gastroprotective activity 
is attributed to the presence of chemical constituents such as tannins 
and flavonoids. Based on this, we have reported the gastroprotective 
activity and some mechanisms involved in the gastroprotection 
elicited by a FRF obtained from A. satureoides inflorescences and the 
anti-H. pylori effect.  
The chemical profile of FRF showed that three main flavonoids may 
be detected by direct comparison with authentic samples, it is 
possible to propose that are luteolin quercetin and 3-O-methyl-
quercetin (3).This results is in accordance with the literature, that 
reports that A. satureoides presents in its composition mainly 
quercetin, luteolin and 3-O-methyl-quercetin[24]. 
Based on chemical composition of FRF, it is expected that it may 
present gastroprotective effect. In fact, here we show that FRF evoke 
a gastroprotection on ethanol-induced ulcer model. Ethanol rapidly 
penetrates the gastric mucosa, and it causes membrane damage, cell 
exfoliation, erosion and ulcer formation. Multiple action mechanisms 
including depletion of non-protein sulfhydryl concentration, 
modulation of the nitric oxide system and reduction of gastric 
mucosal blood flow are involved in the pathogenic 
process[25,26].Recently, Santin et al.[4] showed that ethanol 
administration evoked a rapidly influx of neutrophils into the 
injured tissue and showed that in vivo neutrophil depletion 
significantly reduced the injured area. Newly, Barioniet al.[15] 
showed that A. satureoides hydroalcoholic extractinhibit neutrophil 
influx into the inflammatory area by change the adhesion molecules 
profile. Together, these data show that the gastroprotection evoked 
by FRF could be mediated by an inhibition on neutrophil influx, 
inhibition of gastric secretion or an increase in protective substances 
release by the mucosa. 
Another model largely used is the NSAID-induced ulcer protocol. It is 
known that indomethacin or other NSAIDs display ulcerogenic 
effects associated with the blockade of cyclooxigenase-1 (COX-1) in 
gastric epithelial cells, leading to inhibition of prostaglandins 
synthesis[27,28].Prostaglandins such as E2 and I2
Many experiments of our study were dedicated to the elucidation of 
the mechanism(s) involved in the gastroprotective effect of FRF. One 
simple mechanism of action of FRF might be that the fraction 
interferes with gastric secretion, but our experiments based on the 
model of pylorus ligature clearly show that this mechanism does not 
play a role with respect to FRF. However, FRF treatment evoked a 
increase in mucus secretion, an important mechanism of defense 
 enhance the 
synthesis of mucus and bicarbonate, regulate the acid secretion and 
maintain the integrity of the gastric blood flow in the stomach[29].In 
our hands, FRF 500 mg/kg also showed a gastroprotective effect in 
this model, it reduced the size of the gastric ulcer area in mice 
treated with the NSAID drug indomethacin.  
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that leads to forming a gel, which is composed of phospholipids and 
water, and acts as an antioxidant agent, also being responsible for 
maintaining the neutral pH at the stomach mucosa surface[14]. 
Other important factor to analyze is the NO, which regulates the 
inflammatory and vascular process in the stomach, because NO 
control the integrity of the gastric mucosa and the gastric acid 
secretion[30]. On the other hand, sulfhydryl groups are responsible 
for protecting the gastric mucosa against oxidative damage[31]. 
Intending to evaluated the participation of NO and sulfhydryl groups 
in the protective activity of FRF were employed the pre-treatment 
with L-NAME, a NOS inhibitor, and NEM, a thiol blocker. Our data 
show that the gastroprotective effect is mediated by nitric oxide. 
Additionally, the acetic acid ulcer model, established by Takagi et 
al.[18] was the one that reflects human peptic ulcer disease from the 
view of macroscopic and microscopic observation. For this reason, 
this model has been widely used to study the mechanism of ulcer 
healing and to evaluate the anti-ulcer effect of several compounds. In 
this model, FRF treatment during seven days significantly reduced 
the size of the injury produced by acetic acid when compared to the 
control group. 
Another parameter evaluated was the possible anti-H. pyloriactivity 
of FRF. H. pyloriis a micro-aerophilic, Gram-negative, spiral-shaped 
flagellated bacterium that lives in the stomach and duodenum. It is 
an important causal factor in the pathogenesis of gastritis and ulcer 
disease, inducing gastric inflammation, oxidative stress, DNA 
damage, apoptosis of epithelial cells and inducing cell cycle 
dysregulation[32]. Some abnormalities are linked with H.pylori 
infection, including increased basal and stimulated acid output, 
reduced inhibitory effect of somatostatin on gastrin release, and 
defective inhibition of acid secretion in response to antral 
distension. Our data support that FRF, even at a concentration of 500 
μg/mL, was able to inhibit bacterial growth. 
Taken together, the results show that FRF provided a significant 
gastroprotective and ulcer healing activity, mainly due to their 
capacity to enhance mucus secretion. Moreover, FRF demonstrated 
this activity in a dependent manner of NO, without gastroprotection 
depending on the antioxidant properties of the sulfhydryl groups.  
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